Which statement is true about the monoclonal antibody therapy for RSV?

Palivizumab, a monoclonal antibody therapy for respiratory syncytial virus (RSV), is primarily indicated for use in high-risk infants and children, particularly during their first year of life. This targeted approach is based on the evidence that younger infants, especially those born prematurely or with specific health conditions, are at higher risk of severe RSV disease.

The focus of Palivizumab therapy is to provide passive immunity to these vulnerable populations, reducing the severity and incidence of RSV-related hospitalizations. The treatment is not universally available for all age groups, as indicated in the context of the other options.

Using the therapy in older children or adults is not standard practice, as the risks and types of complications associated with RSV in those populations differ significantly from those in infants. This reinforces the correct statement about the limited applicability of Palivizumab predominantly to those within the first year of life, ensuring that the therapy is utilized in the most effective and risk-appropriate manner.